Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Transformational Data Sharing ETF (BLOK) vs Mesoblast Limited (MESO) Price & Performance

Amplify Transformational Data Sharing ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Amplify Transformational Data Sharing ETF vs Mesoblast Limited — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.16, while Mesoblast Limited trades at $16.68 (market cap $2.21B). Which is the better fit depends on your goals.

BLOKMESO
52-Week High
$74.10$20.96
52-Week Low
$47.36$12.88
Market Cap
$2.21B
Sector
Technology
Enterprise Value
$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Transformational Data Sharing ETF

No Aura AI signal available yet.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Amplify Transformational Data Sharing ETF

The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.

Read more on BLOK

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO